Angiotensin-converting enzyme inhibition and fibrinolytic balance

Hypertension Research

Volumn 34, Issue 4, 2011, Pages 448-449

  Matsumoto, Tetsuya ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; IMIDAPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD PRESSURE REGULATION; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; INTRACORONARY INFUSION; NOTE; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; HYPERTENSION; IMIDAZOLIDINES; INSULIN RESISTANCE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRAZOLES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79953700867     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.3     Document Type: Note

References (15)

1. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001; 87: 18C-24C.
2. Ridderstrale W, Ulfhammer E, Jern S, Hrafnkelsdóttir T. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. Hypertension 2006; 47: 686-691. (Pubitemid 43740239)
3. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angio-tensin II type 1 receptor antagonism on plasma fibri-nolytic balance in humans. Hypertension 1999; 34: 285-290. (Pubitemid 29409229)
4. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin-converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985. (Pubitemid 29270426)
5. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803. (Pubitemid 26225097)
6. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasmino-gen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380. (Pubitemid 30624239)
7. Eriksson P, Van Harmelen V, Hoffstedt J, Lundquist P, Vidal H, Stemme V, Hamsten A, Arner P, Reynisdottir S. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000; 83: 545-548. (Pubitemid 30201128)
8. Fogari R, Zoppi A, Salvadeo SAT, Mugellini A, Lazzari P, Santoro T, Derosa G. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC Study) recipients with hypertension. Hypertens Res 2011; 34: 509-515.
9. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Nishiyama K. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997; 20: 441-445. (Pubitemid 27184937)
10. Erdös EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010; 55: 214-220.
11. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Brady-kinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxy-genase-independent pathway. Circulation 2000; 102: 2190-2196.
12. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, Liao JK. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 2001; 276: 15983-15989.
13. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, Yasuda Y, Ozawa T, Matsuo S, Kinoshita M, Horie M. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373-1379. (Pubitemid 36438999)
14. Matsumoto T, Takashima H, Nakae I, Yamane T, Haya-shi H, Horie M, for the SPAIC (Shiga Plasminogen Activator in Coronary Circulation) Investigators. Angio-tensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men. Hypertension 2010; 56: 364-368.
15. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958. (Pubitemid 46573113)